Integrating immunotherapy in the treatment of resectable gastric cancer: Are we on the right track?

Pazo-Cid, Roberto (Universidad de Zaragoza) ; Gomila Pons, Paula

Resumen: The treatment of locally advanced gastric (G)/gastroesophageal junction (GEJ) adenocarcinoma remains a significant challenge despite advances in chemotherapy (ChT) and surgical techniques. The integration of immune checkpoint inhibitors (ICIs) into the neoadjuvant (NAT) and perioperative treatment regimens is a promising step toward improving outcomes for this patient population.
The phase 2 study reported by Long et al.1 explores the combination of the novel bispecific anti-PD-1/CTLA-4 antibody

Idioma: Inglés

DOI: 10.1016/j.medj.2024.10.020

Año: 2025

Publicado en: Med 6, 3 (2025), 100543 [5 p.]
ISSN: 2666-6359

Tipo y forma: Artículo (PostPrint)

Área (Departamento): Area Medicina (Dpto. Medicina, Psiqu. y Derm.)